Meeder Asset Management’s Kyntra Bio KYNB Stock Holding History

Meeder Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Hold	0	–	–	–	2175
2020 Q1	–	Sell	-20	Closed	-$19.9K	–	2380
2019 Q4	$21K	Sell	20 -1	-5%	-$1.02K	﹤0.01%	1332
2019 Q3	$20K	Buy	+21	New	+$23.1K	﹤0.01%	1311
2019 Q2	–	Sell	-196	Closed	-$264K	–	2061
2019 Q1	$264K	Buy	196 +171	+684%	+$232K	0.02%	489
2018 Q4	$28K	Buy	25 +22	+733%	+$24.7K	﹤0.01%	963
2018 Q3	$5K	Sell	3 -3	-50%	-$4.62K	﹤0.01%	1325
2018 Q2	$9.2K	Buy	6 +3	+100%	+$3.91K	﹤0.01%	1141
2018 Q1	$4K	Sell	3 -52	-95%	-$68.5K	﹤0.01%	1274
2017 Q4	$65K	Buy	55 +31	+129%	+$38.9K	0.01%	636
2017 Q3	$33K	Buy	24 +14	+140%	+$14.8K	﹤0.01%	769
2017 Q2	$8K	Buy	10 +1	+11%	+$697	﹤0.01%	1055
2017 Q1	$6K	Hold	9	–	–	﹤0.01%	1001
2016 Q4	$5K	Buy	+9	New	+$4.49K	﹤0.01%	853

Other funds holding KYNB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Meeder Asset Management's KYNB Position: Q2 2020 in Review

Meeder Asset Management held its Kyntra Bio (KYNB) position steady in Q2 2020 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2175.

Meeder Asset Management first reported a position in KYNB in Q4 2016 and has held it in 12 quarters since. The position peaked at $264K in Q1 2019. 194 funds tracked by Wall St. Rank hold KYNB as of Q2 2020.

Meeder Asset Management held 0 shares of Kyntra Bio worth $0 as of Q2 2020.
Meeder Asset Management left its Kyntra Bio share count unchanged in Q2 2020.
Kyntra Bio made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2020, its #2175 holding.
Meeder Asset Management first reported a position in Kyntra Bio in Q4 2016 and has held it in 12 quarters since.
Meeder Asset Management's Kyntra Bio position peaked at $264K in Q1 2019.
194 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.